Finance

Lists
Q3 2026 earnings • released • EPS miss -81.97% • Revenue miss -0.27%
See results
HIMS:NYSE
Hims & Hers Health Inc
$19.13
-16.61%
(-3.81) 1D
$19.00
-0.69% (-0.13)
After hours
Closed: Nov 10, 4:00:03 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for HIMS...
Open
$22.12
High
$22.47
Low
$18.40
Mkt. cap
4.46B
Avg. vol.
11.55M
Volume
58.76M
52-wk high
$41.28
52-wk low
$13.74
EPS
-$0.63
Beta
2.53
Shares outstanding
224.94M
No. of employees
2K
Open
$22.12
High
$22.47
Low
$18.40
Mkt. cap
4.46B
Avg. vol.
11.55M
Volume
58.76M
52-wk high
$41.28
52-wk low
$13.74
EPS
-$0.63
Beta
2.53
Shares outstanding
224.94M
No. of employees
2K
News stories
From web sources and news partners
Profile
Hims & Hers Health, Inc., doing business as hims, is an American telehealth company headquartered in San Francisco. It provides prescription medications, over-the-counter medications, and personal care products through a direct-to-consumer subscription model. Wikipedia
About Hims & Hers Health Inc
CEO-
Employees2.44K
FoundedNov 2017
HeadquartersSan Francisco, California, United States
SectorHealth Care
IndustryHealth care provider
Website-
Analyst ratings
Based on 13 analysts giving stock ratings to HIMS in the past 3 months
Hold
Buy
3
Hold
10
Sell
0
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for HIMS in the last 3 months.
Highest
Current $19.13
$40.00 (+109.10%)
Average
$29.60 (+54.73%)
Lowest
$24.00 (+25.46%)
Analyst
Recommendation
Action
Price target
Projected
Date
Allen Lutz
Bank of America Securities
Hold
Maintained
-
-
11/10/2026
Michael Cherny
Leerink Partners
Hold
Maintained
$24.00
+25.5%
11/10/2026
Bryan Smilek
J.P. Morgan
Hold
Maintained
$24.00
+25.5%
11/10/2026
Mark Mahaney
Evercore ISI
Hold
Maintained
$27.00
+41.1%
11/10/2026
Brian Tanquilut
Jefferies
Hold
Maintained
$24.00
+25.5%
11/10/2026
Craig Hettenbach
Morgan Stanley
Hold
Reiterated
$25.00
+30.7%
11/10/2026
Ryan MacDonald
Needham
Buy
Reiterated
$32.00
+67.3%
11/10/2026
Maria Ripps
Canaccord Genuity
Buy
Maintained
$40.00
+109.1%
11/10/2026
David Larsen
BTIG
Hold
Maintained
-
-
11/09/2026
Glen Santangelo
Barclays
Buy
Maintained
$35.00
+83%
11/10/2026
Jailendra Singh
Truist Financial
Hold
Reiterated
$32.00
+67.3%
09/11/2026
Justin Patterson
KeyBanc
Hold
Maintained
-
-
09/02/2026
George Hill
Deutsche Bank
Hold
Reiterated
$26.00
+35.9%
08/11/2026
Jonna Kim
TD Cowen
Hold
Reiterated
$30.00
+56.8%
08/11/2026
Daniel Grosslight
Citi
Hold
Maintained
$33.00
+72.5%
08/12/2026
Oliver Chen
TD Cowen
Hold
Reiterated
$25.00
+30.7%
05/12/2026
Cory Carpenter
J.P. Morgan
Buy
Maintained
$33.00
+72.5%
05/12/2026
Unknown Analyst
Nephron
Buy
Upgraded
$35.00
+83%
03/09/2026
Last report
Nov 10, 2026
Fiscal period
Q3 2026
$0.03 / $0.15
-81.97%miss
Revenue / Est. (USD)
890.37M / 892.77M
-0.27%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
598.98M
617.82M
608.10M
753.21M
Cost of goods sold
156.92M
173.38M
182.82M
272.41M
Cost of revenue
156.92M
173.38M
182.82M
272.41M
Research and development expenses
40.58M
40.96M
46.94M
54.90M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
389.67M
386.64M
426.37M
521.95M
Operating expense
430.25M
427.60M
473.31M
576.85M
Total operating expenses
587.17M
600.99M
656.13M
849.26M
Operating income
11.81M
16.83M
-48.02M
-96.04M
Other non operating income
-5.99M
-575.00K
-18.58M
-2.43M
EBT including unusual items
12.22M
18.35M
-101.55M
-92.63M
EBT excluding unusual items
12.22M
21.56M
-61.57M
-96.22M
Income tax expense
-3.55M
-2.25M
-9.44M
-6.34M
Effective tax rate
-29.05%
-12.25%
9.29%
6.85%
Other operating expenses
-
-
-
-
Net income
15.77M
20.60M
-92.12M
-86.29M
Net profit margin
2.63%
3.33%
-15.15%
-11.46%
Earnings per share
0.28
0.22
-0.19
-0.09
Interest and investment income
8.01M
6.80M
7.90M
6.00M
Interest expense
-1.60M
-1.50M
-2.87M
-3.75M
Net interest expenses
6.41M
5.30M
5.03M
2.25M
Depreciation and amortization charges
-
-
-
-
EBITDA
29.48M
34.92M
-26.07M
-66.57M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps